MRNA

Moderna (MRNA)

About Moderna (MRNA)

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Details

Daily high

$42.40

Daily low

$37.76

Price at open

$38.27

52 Week High

$170.47

52 Week Low

$35.80

Market cap

15.8B

Dividend yield

0.00%

Volume

13.4M

Avg. volume

10.0M

P/E ratio

-7.06

Moderna News